Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Because of high protein-binding capacity, clinically significant excretion into breast milk is unlikely. However, both the mother and the infant would benefit of the use of a better-known alternative drug that would be safer while breastfeeding, especially in the neonatal period and in case of prematurity.
In spite of a low excretion into breast milk, it has been described a case of severe apnea in a 12 days old infant. A causal connection between those features and this drug has not been clearly defined (Briggs 2011, p. 410).
It is licensed for use in children from 6 months of age as intestinal antispasmodic and treatment of Familial Mediterranean Fever, so there would be less risky when used by the breastfeeding mother.